PTPN11 and acute lymphoblastic leukemia: This result was of interest because the AKT/mTOR survival pathway is the target of choice in the development of alternative ALL therapies since approximately 30% of pre-B ALL patients display mutations in the signaling molecules that activate AKT, including RAS, PTPN11 and FLT3 [49], [50], [51], [52].